Whether or not glucose-lowering therapy decreases the risk of cardiovascular (CV) mortality and morbidity among patients with type 2 diabetes is a crucial issue. Several large-scale clinical trials have shown the importance of glycemic control from an earlier stage, and the term of metabolic memory or legacy effect for lowering the risk of a CV event is widely known. In contrast, strict glycemic control might rather increase the risk of CV death, especially in patients with a long duration of diabetes and a past history of cardiovascular disease (CVD), probably as a result of severe nocturnal hypoglycemia.
Recently, a number of classes of oral antihyperglycemic drug have been in clinical use. Among them, sulfonylurea (SU) drugs showing the potential effect on blood glucose lowering have been used in the majority of patients with type 2 diabetes for many years. Concerns about CV safety of SU, in contrast, have been raised since the 1970s, when the University Group Diabetes Program suggested an increased risk of CV death as a result of tolbutamide, the first generation of SU 1 . Since then, a significant number of studies in which an increased risk of CV events or death associated with treatment with SU have been documented. Almost all of these studies, however, were based on retrospective analysis, and were not based on the data with confirmation of CV outcomes, showing a lack of confident evidence for the relationship between the incidence of CVD and SU treatment in type 2 diabetes.
A recent report by Li et al. 2 has been meaningful in the discussion of the potential adverse effects of SU on CVD. They prospectively evaluated the data of Nurses' Health Study (NHS), a wellestablished cohort of USA women, to confirm the association between longterm treatment of SU and the incidence of CVD in patients with type 2 diabetes. The NHS cohort was started in 1976, when 121,700 female registered nurses aged 30-55 years sent back a completes mailed questionnaire on their medical history and lifestyle characteristics. The follow-up questionnaires have been sent every 2 years to renew information about potential confounders, including age, bodyweight, smoking status and so on, and potential risk factors and to identify newly diagnosed type 2 diabetes and CVD, and other medical events. A total of 5,536 patients with type 2 diabetes responded to the additional questionnaires regarding their diabetes-related treatment and complications in 2000 and 2005.
Among them, 4,902 participators with the SU therapy information and without diagnosis of CVD at baseline were included in the present study after excluding the participants with prevalent CVD (n = 634) at the time of study initiation. They were divided into two groups; 2,467 non-users and 2,435 users, and followed up during the period of 2000-2010. The use of SU was related to longer duration of diabetes, diabetes-associated complications and use of other oral antihyperglycemic drugs.
In order to assess CV events and mortality, non-fatal myocardial infarction, coronary heart disease (CHD) death and stroke, which was identified primarily by investigating medical records, were included in the end-point of CVD. They requested permission to check medical records when participants reported a non-fatal CHD or stroke, and also confirmed medical records for deceased participants, whose deaths were identified by families and postal officials, and through the National Death Index. Furthermore, physicians blinded to the participant questionnaire reports reviewed all medical records.
Cardiovascular events were confirmed in 339 cases during the follow-up period, including 191 CHD (145 non-fatal myocardial infarction and 46 CHD deaths) and 148 strokes. The multivariable-adjusted relative risks (RRs) of total CVDs were 1.20 (95% confidence interval [CI] 0.91-1.58) for patients whose duration of SU use was 1-5 years at baseline, 1.40 (95% CI 0.98-1.99) for 6-10 years and 1.65 (95% CI 1.12-2.43) for >10 years compared with non-users (Table 1) . When the association of SU use with CHD and stroke was assessed separately, the duration of SU use was significantly related only with CHD, but not stroke. Compared with non-users, the multivariable-adjusted RRs for CHD for patients whose duration of SU therapy for 1-5, 6-10, and >10 years were 1.24 (95% CI 0.85-1.81), 1.51 (95% CI 0.94-2.42) and 2.15 (95% CI 1.31-3.54), respectively (Table 1) . Furthermore, the multivariable RRs of combination therapy with metformin and SU compared with metformin monotherapy were 3.27 (95% CI 1.31-8.17) for CHD ( Table 2) .
The current study clearly showed the association of SU therapy with the risk of CVD, and the RR of CHD was positively correlated with the duration of SU therapy. The continuous SU use for >10 years induced an almost twofold higher risk of CHD in comparison with non-users. The overall findings were consistent with the previous reports from retrospective observational studies.
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The mode of receptor binding is dependent on the structure of SU. Gliclazide targets mainly SUR1, but glibenclamide, glipizide and glimepiride show a high affinity to SUR2A and SUR2B, thereby these three SUs are more harmful for CVD theoretically than glipizide. In contrast, the maximal inhibitory concentration of glibenclamide for closing the K ATP channel is fourfold lower than that of glimepiride, probably because of different post-receptor events. Thus, the influence on CHD could vary according to what kind of SU is used, but the difference in clinical outcomes is not always clear. Zeller et al. 3 showed that the patients previously receiving gliclazide/glimepiride had improved in-hospital outcomes compared with those taking glibenclamide. Klamann et al. 4 , however, reported that in-hospital mortality in patients with type 2 diabetes is higher than in non-diabetic patients suffering acute myocardial infarction regardless of whether or not they had been treated with SUs.
As the other potential reasons for adverse CV effects of SUs, hypoglycemic episodes, weight gain and hypertension have been well documented. The impact of hypoglycemia on incidental CHD is related to several factors, such as endothelial dysfunction, sympathoadrenal response, blood coagulation abnormalities and inflammation. In fact, many trials uncovered a significant relationship between hypoglycemia and CV events and mortality. Furthermore, bodyweight gain might also play a role as a risk factor of CVD. The accumulation of visceral fat has been shown to increase insulin resistance and to deteriorate several CV risk markers (i.e., lipid profiles, blood pressure and high-sensitivity C-reactive protein).
Conversely, there are a number of reports to show a lack of evidence for the association of SU use and CVD risk. Rosenstock et al. 5 suggested that SUs were not related with an increase in CV risk compared with the conventional policy of diet therapy and active comparator (i.e., thiazolidines, metformin, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 analogs) based on 15 published randomized controlled trials.
As described so far, the relationship between SU treatment and CV events is still controversial. The studies including the current cohort trial cannot assess the impact of hypoglycemia, even if confounders, such as the duration of diabetes, diabetes-related complications and other diabetic drugs, could be excluded. It is still ambiguous if the significant association would still be positive even in the cases using a low dosage of SU. The present study by Li et al. showed that a longer duration of SU therapy was related to a higher risk of CHD, but a significant difference might be lost if it is possible to correct it by the SU dosage.
In conclusion, we cannot deny the relationship between SU use and CVD risk in patients with type 2 diabetes. However, it is not yet clear whether SU directly contributes to the increased risk of CVD. Appropriate use in suitable patients with a comfortable level of attention might reduce the risk of hypoglycemia and the incidence of CVD. 
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